These three are routinely compared in terms no supplier can substantiate. What can be compared, and what matters when assessing material, is structural: what each molecule is, how it is built, and what that implies for its analysis.
Receptor targets
- Semaglutide is a GLP-1 receptor agonist. One receptor.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist. Two.
- Retatrutide is described as a triple agonist, adding the glucagon receptor. Three.
The progression looks like a simple ladder and is not one. The compounds differ in which backbone they are built on, which changes the character of the molecule rather than just its reach.
Backbone origin
Semaglutide derives from the native GLP-1 sequence, modified at the DPP-4 cleavage site and carrying a C18 diacid chain attached through a linker at position 26.
Tirzepatide is the structurally interesting one: it is built on a GIP backbone rather than a GLP-1 one, and achieves GLP-1 activity through engineering rather than inheritance. That is a different design starting point from semaglutide, not an extension of it.
Retatrutide is engineered from a GIP-based scaffold with modifications conferring activity across all three receptors.
What they share
All three use the same two strategies against rapid clearance: resistance to DPP-4 cleavage near the N-terminus, and fatty-acid acylation for albumin binding. All three are long sequences by catalog standards, and all three carry the analytical consequences of that length.
All three also incorporate non-standard residues, which is why their synthesis requires building blocks a simpler peptide does not.
What this means for documentation
The practical comparison a buyer can actually make is between certificates, and on these compounds three things deserve attention.
- Observed mass against theoretical. Acylated compounds have a distinctive expected mass, and incomplete acylation produces a species that is mass-detectable but chromatographically close to the parent.
- The chromatogram rather than the purity number. At 39 residues a single deletion is a near-identical molecule, and a flat-looking 99% can sit above a cluster of unresolved shoulders.
- Net peptide content, which at these molecular weights represents a meaningful fraction of vial mass once counterion and residual water are accounted for.
Where comparison stops
Beyond structure, the honest answer is that comparative claims are not something a supplier is positioned to make. Receptor count is a structural fact; what follows from it is a question for published literature, and the answer depends entirely on the model, the endpoint and the conditions.
A supplier can tell you what is in the vial and how that was measured. That is the comparison this page makes, and it is the one that should drive a purchase.
All three compounds are supplied strictly for laboratory research.
Structural comparison answers what these molecules are. What a buyer still has to establish per lot is what arrived, which is a documentation question rather than a structural one: see reading a certificate of analysis line by line and lot-to-lot consistency.
One receptor, two, then three
The structural story across these three compounds is additive. The first engages a single incretin receptor. The second engages two. The third adds a third receptor that the other two do not touch. Each step is a deliberate design choice rather than an incremental refinement, and each one changes what the molecule is being asked to do.
That matters for a buyer because the three are frequently discussed as a progression, as though the later ones were improved versions of the earlier. Structurally they are different molecules engaging different receptor combinations, and published work on one does not transfer to another.
What the backbone contributes
All three are built on peptide backbones related to naturally occurring incretin sequences, with substitutions that change receptor engagement and resistance to the enzymes that would otherwise clear them quickly. The substitutions are where the engineering sits, and they are the reason masses differ substantially between compounds that look superficially similar on a listing.
Reading the mass against the published formula is therefore the fastest way to confirm which of the three a certificate describes. Molecular weight covers the arithmetic, and the gap between these three is large enough that no units confusion could account for it.
Why the fatty-acid chain is the handling story
Each of these carries an acyl chain attached to the backbone, included to bind albumin and extend how long the molecule circulates. That modification dominates the physical behaviour of the material in ways the receptor profile does not.
Specifically, it makes the compound more hydrophobic than its residue composition suggests, which is why these are among the slower compounds in any catalogue to dissolve. Material that appears not to be going into solution is usually behaving normally and needs time rather than force. Why some peptides resist dissolving covers the mechanism.
Comparing certificates across the three
Read the identity method first, because these are long modified peptides where a single intact mass is weaker evidence than it would be for a short sequence. A method that fragments the molecule establishes considerably more, which is the distinction set out in mass spectrometry and peptide identity.
Then read content rather than the label, since these compounds are usually supplied at strengths where a few percent difference is meaningful in any calculation. Net peptide content covers why the two figures differ and which belongs in a calculation.
What varies legitimately between lots
Purity within a narrow band, content within the fill tolerance, and retention time within a small range characteristic of the compound rather than the batch. Those three moving slightly is normal and is what lot-to-lot consistency describes.
What should not vary is the identity result or the mass. A mass that differs between lots of the same compound, with the method unchanged, is a question rather than variation, and it is worth raising before the material is used.
What this comparison deliberately does not cover
Anything about effects. These are research materials supplied for laboratory work, and nothing in a structural comparison speaks to outcomes in any organism. The literature on each compound is extensive and is the place that question belongs.
What a buyer can settle from documentation is narrower and more useful: which molecule is in the vial, how pure it is, how much of it there is, and whether the lot in front of them is the one the certificate describes.
Storage, and why these three behave alike here
Despite differing in receptor profile, all three share the acyl modification that dominates their physical behaviour, which means their storage requirements converge. As dry lyophilised solids they are comparatively robust, and the clock that matters starts at reconstitution rather than at delivery.
In solution the acyl chain introduces a tendency to associate that short unmodified peptides do not have, which is a practical argument for preparing what is needed rather than holding stock in solution. Freeze-thaw cycles and aliquoting covers protecting a reconstituted vial where holding it is unavoidable.
Buying across the three
Treat them as three separate purchasing decisions rather than one category. Each has its own minimum, its own lead time and its own availability, and a supplier able to ship one promptly may be weeks out on another.
Where a formulary carries all three, the practical consequence is that reorder points have to be set per compound rather than per category. Inventory levels and reorder points covers deriving those from measured consumption.
A note on naming and abbreviations
All three circulate under research designations as well as their common names, and listings mix the two inconsistently. A designation is not a guarantee of identity, and two suppliers using the same abbreviation may be describing materials with different modifications.
The mass settles it. Reconciling the certificate figure against the published formula takes a couple of minutes and is the only check that does not depend on trusting the listing.
Reading the literature on these three
Published work on this class is unusually extensive and unusually easy to misapply, because the three compounds are studied in overlapping contexts and summarised together. A finding attached to one receptor combination does not transfer to another, and the differences between these molecules are precisely the differences the research is designed to test.
Two checks make a paper easier to place. Confirm which compound was studied, by its full designation rather than an abbreviation. And confirm the system, because results in one preparation rarely transfer to another without argument.
What a buyer should keep on file
- The compound as the supplier names it, with any research designation they also use.
- The certificate, downloaded rather than linked, naming the lot you received.
- The observed mass, which is the figure that distinguishes these three unambiguously.
- The salt form, which rarely appears on the certificate and exists only in correspondence otherwise.
Those four fields let anyone reading the record later establish exactly which material was used, which a product name alone cannot do.
In short
Three molecules, one, two and three receptors, built on related backbones with an acyl chain that dominates how each behaves physically. The receptor profile is what the research is about. The acyl chain is what the handling is about. The certificate is what the purchase is about, and the mass on it is what tells the three apart.
For where this sits among the other molecules a catalogue carries, not everything in a peptide catalog is a peptide covers how the classes differ.